The next generation?

Article Abstract:

The entry of two arthritis drugs Centocor's Remicade and Immnunex/Amgen's Embrel at pole and second position in the best-selling list of biotech drugs, replacing Amgen's Epogen that had ruled the roost for a long time, indicates a marked shift at the top biologic producers to phase in new 'second-generation' products that maintain market franchises. The goal of production of second-generation products by such companies is to consolidate their foothold in an existing market with an improved product that displaces internal and external competition by maintaining premium price structure.

Production management, Growth, Company growth

---

The emerging nanomedicine landscape

Article Abstract:

A study demonstrated that commercialization efforts are significant, with more than 150 startups and small and medium enterprises (SMEs) pursuing focused nanomedicine R&D projects and 38 nanotechnology-enabled products currently on the market with total sales valued at $6.8 billion. Drug delivery applications in 2006 dominate nanomedicine, accounting for three-quarters of the research activity and of the nanomedicine market.

Sales & consumption, Usage, Technology application, Nanotechnology, Pharmaceutical research, Market size, Industry overview

---

Trendspotting: Betting strong but playing safe

Article Abstract:

Several trends impacting early-to mid-stage life science companies are observed in areas of financing, licensing and collaborations and intellectual property. It is observed that investors find convergent companies as risky, possibly combining the long and uncertain product development life of biotechs with smaller returns on investments of device companies.

Economic aspects

Similar abstracts:

• Abstracts: The next generation. Big Bang: The legacy. Marrying values
• Abstracts: The next generation. Good and hard work
• Abstracts: The man with the money. Sleep easy. Return of the suit
• Abstracts: Calling all exceptional managers. The verge of insanity
• Abstracts: An investigation of the pricing of audit services for financial institutions. To swear early or not to swear early? An empirical investigation of factors affecting CEO's decisions

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.